Reducing Cost and Complexity of Fecal Microbiota Transplantation Using Universal Donors for Recurrent Clostridium difficile Infection.


Journal

Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864

Informations de publication

Date de publication:
08 2019
Historique:
received: 27 03 2019
pubmed: 4 6 2019
medline: 11 6 2020
entrez: 3 6 2019
Statut: ppublish

Résumé

Fecal microbiota transplantation resolves recurrent Clostridium difficile infections in greater than 82% of patients. Highly screened, processed universal donor fecal material is available. We compared cost and scheduling efficiency of fecal microbiota transplantation by universal donors to patient-directed donors. Medical records from a prospectively maintained database of recurrent C. difficile patients who underwent fecal microbiota transplantation between 2012 and 2017 were reviewed retrospectively. Patient-directed donor stool was prepared in our microbiology laboratory using protocol-based screening. We transitioned to purchasing and using universal donor fecal material in 2015. Clinical outcomes, adverse events, time between consult to infusion, consultation fees, and material costs were compared. This was a retrospective comparison of two historical cohorts. A total of 111 fecal microbiota transplantations were performed on 105 patients (56 from patient-directed donors and 55 from universal donors). Median recipient age was 66 years (18-96) with male to female ratio of 1:2.7, equivalent in both cohorts. Total consultation fees were significantly lower in the universal donor group owing to fewer infectious disease consultations. Costs for donor screening and stool preparation were lower in the universal donor cohort ($485.0 vs. $1189.90 ± 541.4, p < 0.001, 95% CI 559.9-849.9). Time from consultations to infusion was shorter in the universal donor cohort (18.9 ± 19.1 vs. 36.4 ± 23.3 days, p < 0.001, 95% CI 9.521-25.591). Recurrences within 8 weeks after fecal microbiota transplantation were equivalent (p = 0.354). Adverse events were equivalent. Fecal microbiota transplantation using universal donors versus patient-directed donors for recurrent C. difficile showed comparable efficacy and short-term complications. The use of universal donors resulted in significant cost savings and scheduling efficiency.

Identifiants

pubmed: 31154629
doi: 10.1007/s12325-019-00974-x
pii: 10.1007/s12325-019-00974-x
pmc: PMC6822862
doi:

Banques de données

figshare
['10.6084/m9.figshare.8035238']

Types de publication

Journal Article

Langues

eng

Pagination

2052-2061

Références

Clin Infect Dis. 2014 Jun;58(11):1515-22
pubmed: 24762631
Am J Gastroenterol. 2013 Apr;108(4):478-98; quiz 499
pubmed: 23439232
Aliment Pharmacol Ther. 2015 Oct;42(8):1011-8
pubmed: 26264455
Am J Gastroenterol. 2013 Apr;108(4):500-8
pubmed: 23511459
Nat Biotechnol. 2014 Sep;32(9):867
pubmed: 25203030
Surgery. 1958 Nov;44(5):854-9
pubmed: 13592638
Ann Intern Med. 2016 Nov 1;165(9):609-616
pubmed: 27547925
JAMA. 2016 Jan 12;315(2):142-9
pubmed: 26757463
Intern Med J. 2016 Apr;46(4):479-93
pubmed: 27062204
N Engl J Med. 2011 Feb 3;364(5):422-31
pubmed: 21288078
Lancet Infect Dis. 2005 Sep;5(9):549-57
pubmed: 16122678
Clin Infect Dis. 2018 Jan 18;66(3):355-362
pubmed: 29106516
Clin Infect Dis. 2011 Nov;53(10):994-1002
pubmed: 22002980
Pharmacotherapy. 2015 Nov;35(11):1016-25
pubmed: 26598094
Infect Control Hosp Epidemiol. 2015 Apr;36(4):438-44
pubmed: 25782899
Clin Infect Dis. 2018 Mar 19;66(7):987-994
pubmed: 29562266
J Infect. 2009 Jun;58(6):403-10
pubmed: 19394704
Am J Gastroenterol. 2014 Jul;109(7):1065-71
pubmed: 24890442
Nat Microbiol. 2016 Feb 24;1:16015
pubmed: 27572174
Am J Gastroenterol. 2012 May;107(5):761-7
pubmed: 22290405
N Engl J Med. 2013 Jan 31;368(5):407-15
pubmed: 23323867
Am J Gastroenterol. 2013 Aug;108(8):1367
pubmed: 23912408
Diagn Microbiol Infect Dis. 2017 Aug;88(4):322-329
pubmed: 28602517
Gastrointest Endosc. 2018 Jan;87(1):18-29
pubmed: 28583769
Aliment Pharmacol Ther. 2012 Apr;35(8):865-75
pubmed: 22360412
Clin Infect Dis. 2016 Apr 1;62(7):908-14
pubmed: 26628567
Clin Gastroenterol Hepatol. 2011 Dec;9(12):1044-9
pubmed: 21871249
N Engl J Med. 2017 Jan 26;376(4):305-317
pubmed: 28121498

Auteurs

Kyeong Ok Kim (KO)

Gastroenterology and Hepatology, Yeungnam University College of Medicine, Daegu, Korea.
Digestive Disease Institute, Virginia Mason Medical Center, Seattle, USA.

Margot A Schwartz (MA)

Section of Infectious Disease, Virginia Mason Medical Center, Seattle, USA.

Otto S T Lin (OST)

Digestive Disease Institute, Virginia Mason Medical Center, Seattle, USA.

Michael V Chiorean (MV)

Digestive Disease Institute, Virginia Mason Medical Center, Seattle, USA.

Michael Gluck (M)

Digestive Disease Institute, Virginia Mason Medical Center, Seattle, USA. Michael.Gluck@virginiamason.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH